• Users Online: 48
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2019  |  Volume : 2  |  Issue : 4  |  Page : 105-106

Intraventricular chemotherapy and nonsmall cell lung carcinoma


Department of Neurology, Federal University of Santa Maria, Santa Maria, RS, Brazil

Date of Submission16-Oct-2019
Date of Decision03-Nov-2019
Date of Acceptance11-Nov-2019
Date of Web Publication25-Feb-2020

Correspondence Address:
Jamir Pitton Rissardo
Rua Roraima, Santa Maria, Rio Grande do Sul
Brazil
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/VIT.VIT_18_19

Rights and Permissions

How to cite this article:
Rissardo JP, Fornari Caprara AL. Intraventricular chemotherapy and nonsmall cell lung carcinoma. Vasc Invest Ther 2019;2:105-6

How to cite this URL:
Rissardo JP, Fornari Caprara AL. Intraventricular chemotherapy and nonsmall cell lung carcinoma. Vasc Invest Ther [serial online] 2019 [cited 2020 Sep 26];2:105-6. Available from: http://www.vitonline.org/text.asp?2019/2/4/105/279226



Dear Editor,

We read the article entitled, “Multiple intraventricular brain metastasis in a case of non-small cell lung carcinoma” on the esteemed “Vascular Investigation and Therapy” with great interest. Kaur et al. reported a case of an elderly male who was diagnosed with nonsmall cell lung cancer presenting with headache and dysarthria. A cranial computed tomography revealed lesions in the intraventricular region, suggestive of brain metastasis.[1]

As Kaur et al. stated metastasis to the choroid plexus, ventricles, pituitary gland, or leptomeninges are rare, and when encountered in the clinical practice, the treatment is a tough decision.[1] In this context, adenocarcinomas are the most common solid tumors to metastasize to the meninges. When lung cancer is analyzed, more than three-quarters of these metastases are related to adenocarcinoma histopathology.[2] The development of new therapeutic options for the systemic treatment of nonsmall cell lung cancer is changing the landscape of this rapidly fatal clinical condition.[3] Herein, we would like to discuss more the leptomeningeal metastasis and intraventricular chemotherapy.

In a recent literature review by Cheng and Perez-Soler, they conclude that more research is needed to understand the biology of the leptomeningeal metastatic development and the drug resistance pathophysiological mechanism. In their management opinion, the patient should already know if he/she is epidermal growth factor receptor (EGFR)-mutant or anaplastic lymphoma kinase-positive because this characterization will divide the treatment in two ways in association with radiotherapy when a diagnosis of leptomeningeal metastasis is done. They also separate the drugs into nonsubstrate-dependent (AZD3759, alectinib) and substrate-dependent (others) based on their efflux transport by p-glycoprotein and breast cancer resistance protein. It is worthy of mentioning that we have more than ten studies that assessed EGFR tyrosine kinase inhibitors, but the data provided by them are still not clear and the statistical power is presumably low, because, in more than 90%, the number of patients in the studies was <30 or the charts were only assessed retrospectively.[4]

Gwak et al. retrospectively studied the outcome of intraventricular management in leptomeningeal carcinomatosis from nonsmall cell lung cancer in more than 100 patients. They found that the elderly, Karnofsky performance score, and uncontrolled intracranial pressure are the prognostic factors for poor outcome. Moreover, even though the median overall survival was of 3 months and a negative conversion of cerebrospinal fluid cytology was observed only in about 8% of the patients, the intraventricular chemotherapy amount significantly improved the overall survival in the multivariate analysis. Therefore, the intraventricular chemotherapy technique not only relieves the symptom but also could increase the survival period in this specific group of patients.[5]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Kaur R, Aggarwal S, Gadhavi S, Dahuja A, Singh P. Multiple intraventricular brain metastasis in a case of non-small cell lung carcinoma. Vasc Investig Ther 2019;2:82.  Back to cited text no. 1
    
2.
Chamberlain MC. Neoplastic meningitis. J Clin Oncol 2005;23:3605-13.  Back to cited text no. 2
    
3.
Christoph DC, Reckamp KL. Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: A feasible and beneficial treatment option? J Thorac Oncol 2013;8:523-4.  Back to cited text no. 3
    
4.
Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol 2018;19:43-55.5.  Back to cited text no. 4
    
5.
Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol 2013;8:599-605.  Back to cited text no. 5
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed370    
    Printed33    
    Emailed0    
    PDF Downloaded48    
    Comments [Add]    

Recommend this journal